Is This The Latest Craze In Healthcare?

Promoters have been pumping it up lately, but is it enough to draw traders in and feast on some action? [Image] Diabetes, cancer, obesity, and cardiovascular diseases have dramatically risen over the last 30 years. Unfortunately, by the time someone is diagnosed, doctors are limited in what they can offer. That’s why we’ve seen a significant push towards preventive and precision medicine over the last five years. Using medical devices to track, monitor, and update your health in real-time and sending that info to your doctor so they can analyze and give you the best help possible. In many cases, these devices save lives. Biotricity, Inc. (Nasdaq: BTCY) wants to make a more effective, easier way to monitor chronic conditions. Promoters have been pumping it up lately, but is it enough to draw traders in and feast on some action? Biotricity, Inc. (Nasdaq: BTCY) - 1-month trading range: $0.595 - 0.82 - Typical average daily volume: ~192,000 - Float: 39.8 million Biotricity’s Business Biotricity is a medical technology company focused on delivering remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. The company’s current product line includes: - Bioflux: The company’s premier product, a mobile cardiac telemetry device that provides real-time monitoring and transmission of an ambulatory patient's ECG Information. - Biotres: An easy-to-wear remote patient monitoring device - Bioheart: award-winning heart rhythm monitor. [0SE9S1-KXXLMn1RHReZxhrIOuBzXkk9wDoH35fAPGX1VqeK-aR20Vx4_RYJh8XgRRs4E0GsfeEJBUnooR-y4CiTH3jkTvobNNaggvn0D1-rVmzNZWtmVv6h_Q575iv7BIC63W41ppZTk_u6wC9bSsA] - Biocare Cardiac: Integrated with diagnostics, this remote patient monitoring device allows cardiac physicians to view continuous data from one patient and adjust interventions and treatment protocols tailored to the individual cardiac patient. - Biokit: A remote patient monitoring solution that creates a personal remote monitoring kit enabling patients to collect multiple data points on temperature, blood pressure, and blood oxygen levels. [2koyrL-4zohet81MlwG4CekXnmXkK-0SbrAlptgnc7hMKGFp4R04X3y8EK15lj5h7RKAZXHRsVLwEdsQTKDz8lzI3rwZ18R48p16M-30mfTSswimKCGU4YaEoYRuqQexMGuIlVrJhRJLEc5YlWUniw] The company also plans to roll out a telemed division in the coming future. Last year, Time Magazine released a list of the best inventions of 2022. One of the inventions mentioned was the Bioheart, which can alert doctors in real-time to problems and inform cardiologists with diagnoses from its data. The Bioheart device is available via subscription, which boasts a retention rate of 98%, which says a lot about the product and service. [5AYNQ2T1AV9uud6h0DeJ06zIoTQ3oJ5a5QRKp57Jiq2RsJ86vmmXegdKB7sWiTlod2t2T13SyDTtLVDDqRhnKacoO963V-hpzB5BxhqmlpO8Nb493IkXHIwbPgWfYqJjASjF-p8iyDEEACHzyVPwHw] Biotricity has surpassed 2 billion recorded and analyzed heartbeats for artificial fibrillation (AFIB). In addition, it received a $250K NIH Grant from the National Heart, Blood, and Lung Institute for AI-Enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure. Financials Biotricity generated $2.46 million in revenue in Q4 2022, an increase of 27.4% YoY. It has made significant strides since March of 2020, when it was making just $1.41 million in revenues. Over the last twelve months, it has made more than $9.0 million. However, its debt is alarming. The company has $887K in cash with total debt of $17.5 million. And while it is making money, it’s not making enough to cover its expenses. For example, its profit margin is -216.7%, and its operating margin is -189.6%. Its operating cash flow of -$16.4 million isn’t pretty…but neither is its EBITDA of -$17.1 million. Let’s call it like it is…Biotricity needs some cash. Promoter Activity At the moment, I received emails from two different promoters about this company. They started on April 17th. The first promoter highlights these potential catalysts: - Zacks Small-Cap Research gives it a price target of $7.50 - The company’s revenue growth increased by 27.4%, and high retention rate on its recurring revenue. - The company signed a new distribution agreement that could boost revenues in the future - Stock has a relatively low float - Awards by Time Magazine They go on to talk about how Biotricity’s monitoring devices can help prevent diseases and emergencies in advance. And how it has expanded its network to 100+ centers across 30+ states with 2,000+ physicians. The second promoter highlights many of the same bullish points, like: - Signed agreements with two leading US medical device distributors and one GPO. - The company’s revenues are up from last year - High retention rate on its subscription medical devices They do a full run down on the latest press releases from BTCY, the latest earnings report, and bios of the company’s management. While both promoters do a good job of highlighting the company, both fail to deliver on the “why now” question. The first promoter was paid $14,500 to bring one-day awareness to BTCY on April 17. They have done six other campaigns in the past and have received $110,500. The second promoter has been compensated $636,500 in total. They have been doing awareness campaigns on and off since September of 2021 for BTCY. The latest campaign is from 4/17 to 4/20, in which they’re getting paid $37,500 for their services. Straight to the Facts Biotricity is missing a catalyst. The company’s medical devices are an excellent preventive healthcare solution. However, they need more positive feedback or a way to tie in their devices to a hot trend like AI. We have seen a jump in trading volume recently. But, without an ultra-low-float, high short-interest, or exciting catalyst, it’s hard to see this stock-taking off. Nonetheless, it’s worth keeping on your radar for the next few days. Always at your service, Baron Von Stocks Disclosure: I am not a fin-an-cial adviser. All potential percentage gains are based on from the low to the high of day. Prime Tech Stocks full disclosure is to be read and fully understood before using Prime Tech Stocks website, or joining Prime Tech Stocks’ email or text list. By viewing Prime Tech Stocks website and/or reading Prime Tech Stocks email or text newsletter you are agreeing to Prime Tech Stocks full disclosure which can be read at www (dot) primetechstocks (dot) com/disclosure/ Make sure to always do your own research and due diligence on any day and swing profile brought to your attention. Prime Tech Stocks owned by Red Oak Media Group LLC, a limited liability company. Red Oak Media Group's full disclosure document can be read at www (dot) primetechstocks (dot) com/disclosure/ We do not own any shares in BCTX. We have been compensated up to Ten Thousand Dollars via bank wire transfer from a third-party Winning Media LLC for a 1 Day Marketing Program regarding BCTX with a start date of 4/17/2023 to 4/18/2023. Red Oak Media Group, 7940 Ann Arbor St Dexter MI USA 48130 To update contact information or unsubscribe from this list, please [click here](